Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develop… Read more
Orchestra BioMed Holdings Inc. (OBIO) - Total Assets
Latest total assets as of September 2025: $104.81 Million USD
Based on the latest financial reports, Orchestra BioMed Holdings Inc. (OBIO) holds total assets worth $104.81 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Orchestra BioMed Holdings Inc. - Total Assets Trend (2020–2024)
This chart illustrates how Orchestra BioMed Holdings Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Orchestra BioMed Holdings Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Orchestra BioMed Holdings Inc.'s total assets of $104.81 Million consist of 90.8% current assets and 9.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 29.2% |
| Accounts Receivable | $92.00K | 0.1% |
| Inventory | $173.00K | 0.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Orchestra BioMed Holdings Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Orchestra BioMed Holdings Inc.'s current assets represent 90.8% of total assets in 2024, a decrease from 95.2% in 2020.
- Cash Position: Cash and equivalents constituted 29.2% of total assets in 2024, down from 53.4% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 0.2% of total assets.
Orchestra BioMed Holdings Inc. Competitors by Total Assets
Key competitors of Orchestra BioMed Holdings Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Orchestra BioMed Holdings Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Orchestra BioMed Holdings Inc. generates 0.03x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Orchestra BioMed Holdings Inc. is currently not profitable relative to its asset base.
Orchestra BioMed Holdings Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.73 | 4.23 | 12.00 |
| Quick Ratio | 4.72 | 4.21 | 12.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $77.11 Million | $ 52.34 Million | $ 1.92 Million |
Orchestra BioMed Holdings Inc. - Advanced Valuation Insights
This section examines the relationship between Orchestra BioMed Holdings Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.96 |
| Latest Market Cap to Assets Ratio | 1.97 |
| Asset Growth Rate (YoY) | -20.0% |
| Total Assets | $76.17 Million |
| Market Capitalization | $150.17 Million USD |
Valuation Analysis
Above Book Valuation: The market values Orchestra BioMed Holdings Inc.'s assets above their book value (1.97 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Orchestra BioMed Holdings Inc.'s assets decreased by 20.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Orchestra BioMed Holdings Inc. (2020–2024)
The table below shows the annual total assets of Orchestra BioMed Holdings Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $76.17 Million | -20.00% |
| 2023-12-31 | $95.21 Million | -0.38% |
| 2022-12-31 | $95.57 Million | +606.53% |
| 2021-12-31 | $13.53 Million | -64.49% |
| 2020-12-31 | $38.09 Million | -- |